Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Valproic acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Valproic acid. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2004-004320-13 Sponsor Protocol Number: AMLSG 06-04 Start Date*: 2005-08-29
    Sponsor Name:Universitätsklinikum Ulm / University Clinical Center Ulm
    Full Title: RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004278-41 Sponsor Protocol Number: 01081 Start Date*: 2010-04-19
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.
    Medical condition: This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011723-31 Sponsor Protocol Number: VPA-study Start Date*: 2009-12-09
    Sponsor Name:Västra Götalandsregionen
    Full Title: Effects of valproic acid on fibrinolysis in man
    Medical condition: This is a healthy volunteer trial. The intended indication for the product is to investigate if upregulation of the tPA-gene by valproic acid results in increased tPA-release from endothelium in f...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016603 Fibrinolysis LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2008-002649-22 Sponsor Protocol Number: D1443L00058 Start Date*: 2009-01-23
    Sponsor Name:AstraZeneca Farmacéutica Spain, S.A.
    Full Title: Efectividad de quetiapina de liberación prolongada vs sertralina como terapia co-adyuvante al tratamiento eutimizante previo en la depresión bipolar aguda: un estudio piloto
    Medical condition: Depresión bipolar aguda
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004321-95 Sponsor Protocol Number: AMLSG 07-04 Start Date*: 2005-05-26
    Sponsor Name:University of Ulm
    Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI...
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001523-69 Sponsor Protocol Number: V-CHANCE Start Date*: 2014-07-28
    Sponsor Name: Istituto Nazionale Tumori di Napoli - Fondazione "G. Pascale"
    Full Title: Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck
    Medical condition: Recurrent and/or metastatic squamous cell carcinoma of head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002837-48 Sponsor Protocol Number: HEAL-1-v1.5 Start Date*: 2017-12-22
    Sponsor Name:Erasmus MC
    Full Title: HIV Eradication by combining Agents to reverse Latency in vivo (HEAL-1): a randomized controlled trial.
    Medical condition: Adults with human immunodeficiency virus type-1 infection on antiretroviral treatment with adequate viral suppression and good cellular immunity.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004454-27 Sponsor Protocol Number: AZAVATRA_V01 Start Date*: 2006-09-18
    Sponsor Name:Heinrich-Heine-Universität
    Full Title: Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen e...
    Medical condition: Myelodysplastisches Syndrom und andere myeloische Neoplasien
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001092-49 Sponsor Protocol Number: VPA-03 Start Date*: 2015-06-02
    Sponsor Name:Sahlgrenska Akademien Wallenberglaboratoriet
    Full Title: Valproic acid regulation of plasma PAI-1
    Medical condition: The fibrinolytic system
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10016611 Fibrinolytic activity increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004950-27 Sponsor Protocol Number: VAL-02 Start Date*: 2014-02-06
    Sponsor Name:Sahlgrenska universitetssjukhuset
    Full Title: Effect of valproic acid on fibrinolysis in humans with atherosclerosis
    Medical condition: Atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005090-65 Sponsor Protocol Number: VALPAX Start Date*: 2007-10-18
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours
    Medical condition: Patients with anaplastic thyroid cancer or with metastatic solid tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002240 Anaplastic thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003554-15 Sponsor Protocol Number: 18031977 Start Date*: 2006-11-09
    Sponsor Name:National Cancer Institute
    Full Title: The histone deacetylase inhibitor (HDAC) valproic acid as second line treatment for hormone refractory metastatic prostate cancer. A phase II. study.
    Medical condition: hormone refractory metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018284-42 Sponsor Protocol Number: LEVVPA Start Date*: 2012-12-19
    Sponsor Name:University Medical Centre Groningen
    Full Title: Double-blind randomized trial comparing efficacy, safety and tolerance between Levetiracetam monotherapy and Valproic acid monotherapy in children with newly diagnosed epilepsy
    Medical condition: epilepsy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005221-11 Sponsor Protocol Number: MUTAVA Start Date*: 2008-10-22
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel.
    Medical condition: Patients with undifferentiated thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002240 Anaplastic thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003198-17 Sponsor Protocol Number: UZB_20160728 Start Date*: 2016-09-29
    Sponsor Name:Universitair Ziekenhuis Brussel Vrije Universiteit Brussel
    Full Title: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
    Medical condition: Treatment of Idiopathic Nephrotic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000418-35 Sponsor Protocol Number: TT-AVUGANE-Acne-02 Start Date*: 2007-05-22
    Sponsor Name:TopoTarget A/S
    Full Title: A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects w...
    Medical condition: Acne vulgaris of mild to moderate intensity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004811-31 Sponsor Protocol Number: GIMEMA MDS 0205 Start Date*: 2006-05-16
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO
    Full Title: An open label, phase II, non randomized, clinical trial of chemotherapy treatment with 5-Azacytidine plus valproic acid and eventually atra for patients diagnosed with Intermediate II and high risk...
    Medical condition: Intermediate II and high risk Myelodysplastic syndrome MDS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022444-20 Sponsor Protocol Number: 40-41200-98-9069 Start Date*: 2010-11-15
    Sponsor Name:ZonMW
    Full Title: PHASE I-II STUDY OF GEMCITABINE AND VALPROIC ACID PLUS VALGANCICLOVIR IN PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA
    Medical condition: Patient has histological confirmed residual, recurrent or metastatic EBV-positive Nasopharynx carcinoma that has failed conventional curative treatments and deemed incurable, or patient refuses fur...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004091-35 Sponsor Protocol Number: EMC-NET1 Start Date*: 2019-04-19
    Sponsor Name:Erasmus University Medical Center
    Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
    Medical condition: Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078174 Neuroendocrine tumour of the lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:53:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA